Clinical trials: Short-course Radiotherapy Plus Chemotherapy
Short-course Radiotherapy Plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer
Safety and efficacy of Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab versus Short-course Radiotherapy plus Chemotherapy as Total Neoadjuvant…
- Trial name
- SPARK II (NCT07674732)
- Testing
- Short-course Radiotherapy plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Dechang Diao
Glioblastoma
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions…
- Trial name
- NCT04019262
- Testing
- Radiation Therapy, Temozolomide Oral Product
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- John Flickinger
Rectal Cancer, Radiotherapy
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
- Trial name
- NCT07239466
- Testing
- Short-course radiotherapy, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tao Zhang
Endometrial Cancer, Stage III Endometrial Cancer
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able…
- Conditions
- Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma
- Trial name
- NCT05691010
- Testing
- Intensity-modulated radiation therapy, Carboplatin, Paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Microsatellite stable (MSS) locally advanced rectal cancer (LARC) remains a major therapeutic challenge despite advances in multimodal treatment.
- Trial name
- NCT07594925
- Testing
- Sintilimab, Chemotherapy Drugs, radiotherapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer, Locally Advanced
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma
- Trial name
- NCT05868317
- Testing
- Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy
- Where
- Tunisia
- Volunteers
- 70 people
- Sponsor
- Salah Azaïz Cancer Institute
Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma
This study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal…
- Trial name
- POSIT (NCT07674342)
- Testing
- Short-course Radiotherapy, Neoadjuvant Serplulimab and SOX Chemotherapy
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Tongji Hospital
Rectal Cancer, Neoadjuvant Therapies
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Most rectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) and respond poorly to PD-1 inhibitors. Radiotherapy can enhance tumor antigen release and improve responsiveness to PD-1 blockade in…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06958432
- Testing
- Node-Sparing Radiotherapy plus Chemotherapy and PD-1 inhibitor, Conventional Radiotherapy plus Chemotherapy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Locally Advanced Rectal Cancer (LARC)
Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
Standard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery.
- Trial name
- NCT07581626
- Testing
- SCRT+targeted therapy+immunotherapy+chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Rectal Neoplasms Malignant, Radiotherapy
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
This phase II/III trial studies how well neoadjuvant short-course radiotherapy and chemotherapy with or without PD-1 inhibitors works in treating patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT05484024
- Testing
- Sintilimab, Short-course radiotherapy, CAPOX/mFOLFOX
- Where
- 2 sites in China
- Volunteers
- 588 people
- Sponsor
- Chinese Academy of Medical Sciences
Rectal Cancer
Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining DCSZ11 with radiation and capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with mismatch repair proficient (pMMR)…
- Trial name
- NCT07580339
- Testing
- DCSZ11, Radiation, Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoadjuvant Treatment, Rectal Cancer
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Bevacizumab, Radiotherapy
- Trial name
- NCT05111860
- Testing
- Bevacizumab+mFOLFOX6
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Locally Advanced Colon Cancer
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
The study evaluates the combination of immunotherapy of PD-1 antibody and chemotherapy and neoadjuvant short-course radiotherapy in locally advanced colon cancer (LACC).
- Trial name
- TORCH-C (NCT05732493)
- Testing
- Serplulimab, short-term radiotherapy, Oxaliplatin
- Volunteers
- 120 people
- Sponsor
- Fudan University
Advanced Rectal Cancer, Distal Metastasis
A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis
Though surgical resection remains the primary choice for advanced rectal cancer, about 80% are considered unresectable due to the number, size, or location of metastases.
- Trial name
- Miracle-2 (NCT05359406)
- Testing
- a combination therapy including tislelizumab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- LI XIN-XIANG
Rectal Cancer
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally…
- Trial name
- TRIUNITE-03 (NCT06718543)
- Testing
- AK112 with SCRT and CapeOX, AK112 with SCRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- fan li
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer
The goal of this clinical trial is to test a new combination treatment for locally advanced rectal cancer (cancer in the lower or middle part of the rectum that has not spread to distant organs).
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07397442
- Testing
- Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Beijing Friendship Hospital
Rectal Cancer, Radiotherapy
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
This is a open-label, single-arm study to investigate the safety and efficacy of consolidative chemotherapy with camrelizumab, an anti-PD-1 antibody drug following short course radiotherapy and subsequent surgical therapy in…
- Conditions
- Rectal Cancer, Radiotherapy, Immunotherapy
- Trial name
- NCT04231552
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastroesophageal Adenocarcinoma
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
- Trial name
- NCT04021108
- Testing
- Nivolumab 240 MG
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Weill Medical College of Cornell University
Locally Advanced Rectal Cancer (LARC)
A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
In a single-center, prospective, phase II study (ClinicalTrials registration number: [to be filled in]) initiated by our center to evaluate the safety and preliminary efficacy of short-course radiotherapy followed by sequential…
- Trial name
- NCT07347951
- Testing
- Short-course radiotherapy, CAPOX chemotherapy, Targeted therapy with bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Rectal Cancer, Total Neoadjuvant Treatment
Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer
Short-course radiotherapy followed by consolidation chemotherapy has shown a better response rate when compared to chemoradiotherapy treatment.
- Trial name
- SHORT-ICAR (NCT04674696)
- Testing
- Approach
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Instituto Nacional de Cancer, Brazil